Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential TherapyHidekatsu Kuroda, Yasuhiro Takikawa, Takayoshi Oikawa et al.|Liver Cancer|2022Cited by 45
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, JapanMasashi Fujita, Hiromasa Ohira, Kazumichi Abe et al.|Scientific Reports|2022Cited by 17
Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective StudyHideto Kawaratani, Hitoshi Yoshiji, Kei Endo et al.|Journal of Clinical Medicine|2022Cited by 16
Serum prolactin levels and prolactin m<scp>RNA</scp> expression in peripheral blood mononuclear cells in hepatitis C virus infectionRika Ishii, Sumio Kawata, Takafumi Saito et al.|Journal of Medical Virology|2013Cited by 9